Autoantibodies to cytokines - friends or foes?

Bendtzen, Klaus; Svenson, Morten; Jønsson, Viggo; Hippe, Erik

doi:10.1016/0167-5699(90)90068-k

Cited by 211 publications

(88 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accordingly, it is possible that IL-6 may modulate the inflammatory and immunologic process of SSc, and anti-IL-6 autoantibodies may prolong the bioactivity of the cytokine in vivo, as suggested by Bendtzen et a1 (6). Further studies on the participation and precise roles of IL-6 in the pathogenesis of SSc will be required for elucidation of these issues.…”

Section: Discussionmentioning

confidence: 92%

Anti–interleukin‐6 autoantibodies in rheumatic diseases

Takemura

Suzuki

Yoshizaki

et al. 1992

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To investigate the presence and the roles of anti–interleukin‐6 (anti–IL‐6) autoantibodies in rheumatic diseases, and to further elucidate clinical and pathophysiologic significance of anticytokine autoantibodies. Methods. Anti–IL‐6 IgG autoantibodies were measured by the 125I–IL‐6 binding activity of IgG, which was isolated from serum by protein A–Sepharose. Results. Nine of 52 sera (17.3%) from patients with systemic sclerosis (SSc) contained anti–IL‐6 antibodies, whereas only 1.9% of sera from normal subjects and 0–5% of sera from patients with other rheumatic diseases were positive for the antibodies. Moreover, anti–IL‐6 autoantibodies were found predominantly among patients with the limited form of SSc (42.9%), compared with those with the diffuse form (7.9%). Conclusion. Anti–IL‐6 IgG autoantibodies were detected in patients with SSc, particularly those with the limited form of the disease, at a significantly increased frequency compared with normal subjects and patients with other rheumatic diseases. These results suggest that the development of anti–IL‐6 autoantibodies and IL‐6 may have a role in the pathophysiology of SSc.

show abstract

Section: Discussionmentioning

confidence: 92%

Anti–interleukin‐6 autoantibodies in rheumatic diseases

Takemura

Suzuki

Yoshizaki

et al. 1992

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…IgM and IgG antibodies against interleukin-lot (IL -la) have been shown in serum and human epidermis [10], which would imply a pathophysiological role for IL-1 in the systemic features of this syndrome. However, the physiological role of circulating auto-antibodies is not clear at all, because auto-antibodies (mostly of the IgG but sometimes also IgM) are detectable in 24% of apparently normal adults [11].…”

Section: Discussionmentioning

confidence: 99%

Schnitzler's syndrome presenting as fever of unknown origin (FUO) The role of cytokines in its systemic features

Kleijn

Telgt

Laan

1997

The Netherlands Journal of Medicine

View full text Add to dashboard Cite

A patient with Schnitzler's syndrome is described presenting with fever of unknown origin. Although he had all characteristic features of the syndrome (urticarial vasculitis, hyperostosis, lymphadenopathy, fever and serum IgM monoclonal component), it was recognized very late in the diagnostic process. Cytokines were measured to get more insight into the role of cytokines in this syndrome, but only interleukin-6 was elevated. It is important for internists and rheumatologist to recognize this entity in order to prevent unnecessary diagnostic procedures. © 1997 Elsevier Science B.Y.

show abstract

“…Bendlzen et al [32] have reviewed lhe role of autoaniibodies lo cytokines. and have suggested that anti-cytokine antibodies (neutralizing type) may produce 'eylokine deficiency", thus inhibiting their functions, while in some eases they (non-neutralizing type) contribute to a positive therapeutic response by better targeting to the appropriate cells.…”

Section: Discussionmentioning

confidence: 99%

Active immunization by a dengue virus-induced cytokine

Chaturvedi¹,

Mukerjee²,

Dhawan³

1994

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYDengue type 2 virus (DV)-induccd cytotoxic factor (CF) is capable of reproducing various palhological lesions in mice that are seen in human dengue. The present study was undertaken to investigate the protective effect of active immunization of mice with CF, Mice were immunized with 5 //gof CFand prevention ofCF-induced increase in capillary permeability and damage to the bloodbrain barrier were studied at weekly intervals, up to 48 weeks, by challenging with } /(g of CF, Maximum protection against increase in capillary permeability and damage to the blood-brain barrier was observed in week 4 after immunization. A breakthrough in the protection occurred with higher doses of CF in a dose-dependent manner. Challenge with a lethal intraccrcbrat (i.e.) dose of DV showed significantly prolonged mean survival time and delayed onset ofsymptoms of sickness in the immunized mice compared with the normal mice, but the titre ofthe virus in the brain was similar in the two groups. On i,p. challenge with the virus the protection against damage to the blood-brain barrier was 86 + 7",' ;i at week 4 and 17 + 4% at week 26 after immunization. Sera obtained from the immunized mice showed the presenee of CF-sp>eeific antibodies by ELISA, Western blot, and by neutralization of the cytotoxic activity of CF in vitro. The present study describes successful prevention ofa cytokine-induced pathology by speeific aetive immunization.

show abstract

Autoantibodies to cytokines - friends or foes?

Cited by 211 publications

References 26 publications

Anti–interleukin‐6 autoantibodies in rheumatic diseases

Anti–interleukin‐6 autoantibodies in rheumatic diseases

Schnitzler's syndrome presenting as fever of unknown origin (FUO) The role of cytokines in its systemic features

Active immunization by a dengue virus-induced cytokine

Contact Info

Product

Resources

About